Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004135 (
ATM
)
13,001
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified a novel, membrane-located protein that interacts specifically with the carboxyl-terminal cytoplasmic domain of the AT1a receptor, which we named
ATRAP
(for AT1 receptor-associated protein). To further investigate the role of
ATRAP
in
AT1
receptor function, we examined the effect of overexpression of
ATRAP
on angiotensin II (Ang II)-induced
AT1
receptor desensitization and/or internalization, and cell proliferation in adult vascular smooth muscle cells (VSMCs). Transfection of
ATRAP
potentiated
AT1
receptor internalization upon Ang II stimulation in these VSMCs. Moreover, we observed that
AT1
receptor-induced DNA synthesis was markedly inhibited in
ATRAP
transfected VSMCs associated with the inhibition of the phosphorylation of signal transducers and activators of transcription (STAT) 3 and Akt. Our results suggest that
ATRAP
functions as a negative regulator in
AT1
receptor-mediated cell proliferation in VSMCs.
...
PMID:ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. 1116 53
The
AT1
receptor (AT1R)-associated protein (
ATRAP
) is a molecule specifically interacting with the carboxyl-terminal domain of AT1R. The results of in vitro studies showed that
ATRAP
suppresses Ang II-mediated pathological responses in cardiovascular cells by promoting AT1R internalization. With respect to the tissue distribution and regulation of
ATRAP
expression in vivo,
ATRAP
is broadly expressed in many tissues as is AT1R. Accumulating evidence indicates that a tissue-specific regulatory balancing of
ATRAP
and AT1R expression may be involved in the modulation of AT1R signaling at local tissue sites and also in the pathophysiology of hypertension and its associated end-organ injury. Furthermore, the activation of
ATRAP
in transgenic-models inhibited inflammatory vascular remodeling and cardiac hypertrophy in response to Ang II stimulation. These results suggest the clinical potential benefit of an
ATRAP
activation strategy in the treatment of hypertension and related organ injury.
...
PMID:[Physiology of novel AT1 receptor-binding molecule, ATRAP]. 2301 94